
Bal Pharma Ltd is Rated Hold by MarketsMOJO
2026-11-19 10:10:57Bal Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 11 November 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 November 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Bal Pharma Ltd Locks at Lower Circuit With 4.99% Loss — Sellers Queue, No Buyers in Sight
2026-11-16 14:00:09At Rs 86.40, sellers were still queuing — but there were no buyers willing to take the other side. Bal Pharma Ltd locked at its lower circuit of 4.99% on 16 Nov 2026, with unfilled sell orders and a frozen price, reflecting a constrained exit environment for shareholders.
Read MoreBal Pharma Surges 9.50% in a Week: Key Drivers Behind the Rally
2026-11-14 17:00:46Key Events This Week Nov 09: Stock opens at Rs.83.41, up 1.37% Nov 11: Continued gains with Rs.84.03 close (+0.74%) Nov 12: Upper circuit hit at Rs.88.10 (+4.99%) amid strong buying and Q2 results Nov 13: Week closes at Rs.90.10 (+2.12%) Week OpenRs.82.28 Week CloseRs.90.10<div class="sta...
Read More
Bal Pharma Ltd is Rated Sell by MarketsMOJO
2026-10-31 10:10:13Bal Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 October 2026, providing investors with the latest insights into the company’s performance and outlook.
Read MoreBal Pharma Ltd Falls 14.87%: Downgrade and Lower Circuit Hit Drive Sharp Decline
2026-10-24 17:02:16Key Events This Week 19 Oct: Downgrade to Sell rating by MarketsMOJO 23 Oct: Stock hits lower circuit limit at Rs.80.35 23 Oct: Seventh consecutive day of losses 23 Oct: Week closes at Rs.81.60 (-14.87%) Week OpenRs.95.85 Week CloseRs.81.60-14.87%</...
Read More
Bal Pharma Ltd Upgraded to Hold as Technicals Improve and Valuation Attractiveness Increases
2026-10-15 08:11:25Bal Pharma Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in its technical indicators and valuation metrics despite flat recent financial performance. The upgrade, effective from 14 October 2026, is driven primarily by a bullish shift in technical trends, attractive valuation relative to peers, and a stable financial trend, positioning the micro-cap pharmaceutical company as a cautious but watchful pick for investors.
Read More
Bal Pharma Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent
2026-10-12 11:00:12At Rs 97.71, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bal Pharma Ltd locked at its upper circuit of 5.0% on 12 Oct 2026, with buyers queuing and no sellers willing to part with shares.
Read More
Bal Pharma Ltd Downgraded to Sell Amid Mixed Fundamentals and Technical Signals
2026-10-12 08:07:25Bal Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 09 Oct 2026. This shift reflects a complex interplay of technical indicators, valuation metrics, financial trends, and quality assessments, signalling caution for investors despite some attractive valuation parameters.
Read MoreBal Pharma Ltd Falls 13.43%: 4 Key Events Shaping This Week’s Decline
2026-10-10 17:01:07Key Events This Week 5 Oct: Week opens at ₹107.60 6 Oct: Shares plunge to lower circuit amid heavy selling pressure 7 Oct: Upgraded to Hold as valuation and technicals improve; hits lower circuit again 9 Oct: Week closes at ₹93.15, down 13.43% Week OpenRs.107.60 Week CloseRs.93.15<div cla...
Read MoreNewspaper Publications - Unaudited Financial Results 30Th September 2026
12-Nov-2026 | Source : BSEIn Continuation of outcome of Board meeting dated 11th November 2026 published unaudited financial result for the 02nd quarter and half year ended 30th September 2026. Copy of the newspaper publication enclosed.
Board Meeting Outcome for Outcome Of Board Meeting
11-Nov-2026 | Source : BSEAs intimated vide our letter dated November 03 2026 Board of directors of the Company met on Wednesday November 11 2026 inter alia transacted the following business.
Unaudited Standalone And Consolidated Financial Results For The Second Quarter And Half Year Ended On 30Th September 2026 Along With The Limited Review Report
11-Nov-2026 | Source : BSEEnclosed unaudited standalone and consolidated Financial Result of Second quarter 30th September 2026 along with Limited Review Report
Corporate Actions
No Upcoming Board Meetings
Bal Pharma Ltd has declared 12% dividend, ex-date: 17 Sep 26
No Splits history available
No Bonus history available
No Rights history available